Encompass Health Corporation (EHC) SEC Filings & Earnings Calls
EquiReason read 15 Encompass Health Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 12.2B
- P/E TTM
- 20.2
- Dividend yield
- 0.6%
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 20268-K · 8.01Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance of existing $500M notes from May 2026.open
Figures in the filing · each found in the filing text
| Additional Notes Principal · 2026-08-13 | $100M | |
| Net Proceeds · 2026-08-13 | $97M | |
| Coupon Rate · 2026-08-13 | 5.9% |
Risks flagged
Increased debt leverage with $100M additional notes, though used to repay revolver.
“Issuance of $100M additional 5.875% senior notes due 2034.”
7 Aug 202610-QCMS released final rule for IRF FY2027 with net 2.3% payment increase, while RCD expanded to Texas and California, affecting 33 Encompass IRFs.open
Figures in the filing · each found in the filing text
| Medicare payment rate increase · FY2027 | 2.3% | |
| IRFs subject to RCD · 2026-06-30 | 33 |
Risks flagged
Medicare review choice demonstration expansion
“As of June 30, 2026, we have 33 of our IRFs (representing approximately 11.9% of our IRF Medicare claims) subject to RCD.” · word for word
Regulatory compliance cost
“RCD increases administrative burden and potential claim denials.”
Reimbursement risk
“Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors... could decrease our revenues.” · word for word
5 Aug 20268-K · 2.02, 7.01Net Operating Revenue $1.60B (+10% y/y); Adjusted EBITDA $348M (+9% y/y); Adjusted EPS $1.55 (+11% y/y); Guidance: FY revenue guidance raised to $6.41-6.49B from $6.375-6.47B; adjusted EBITDA to $1.365-1.395B from $1.35-1.38B; adjusted EPSearningsopen
Figures in the filing · each found in the filing text
| Net Operating Revenue · Q2-2026 | $1.60B | +10% y/y |
| Adjusted EBITDA · Q2-2026 | $348M | +9% y/y |
| Adjusted EPS · Q2-2026 | $1.55 | +11% y/y |
| Discharges · Q2-2026 | 68,895 | +6% y/y |
| Same-store Discharge Growth · Q2-2026 | 2.8% | |
| Net Patient Revenue per Discharge · Q2-2026 | $22521.00 | +4% y/y |
| Cash Flows from Operating Activities · Q2-2026 | $283M | +5% y/y |
| Adjusted Free Cash Flow · Q2-2026 | $177M | -5% y/y |
Guidance
FY revenue guidance raised to $6.41-6.49B from $6.375-6.47B; adjusted EBITDA to $1.365-1.395B from $1.35-1.38B; adjusted EPS to $6.02-6.25 from $5.89-6.11
Raised full-year guidance across all key metrics, reflecting strong volume growth and operating leverage.
Risks flagged
Labor cost pressure and reimbursement risk in healthcare.
“No explicit risk factors discussed, but industry-wide labor and reimbursement pressures are typical.”
1 May 202610-QMedicare payment rate increase 2.4; IRFs subject to RCD 33; Guidance: Proposed net Medicare payment rate increase of 2.4% effective October 1, 2026open
Figures in the filing · each found in the filing text
| Medicare payment rate increase · IRF · FY2027 | 2.4% | |
| IRFs subject to RCD · IRF · 2026-05-01 | 33 |
Guidance
Proposed net Medicare payment rate increase of 2.4% effective October 1, 2026
CMS proposed a net 2.4% market basket increase for IRF Medicare payments for FY2027, which the company estimates will result in a net 2.4% increase to its Medicare payment rates.
Risks flagged
Medicare reimbursement dependency
“We are highly concentrated in our primary line of business, particularly with respect to Medicare regulations and reimbursement.” · word for word
Regulatory compliance burden from RCD expansion
“With the expansion to those two states, we expect 33 of our current inpatient rehabilitation hospitals (representing approximately 11.9% of our IRF Medicare claims) to be subject to RCD.” · word for word
Staffing shortages
“Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results and has done so in the past.” · word for word
7 Apr 2026DEF 14AAnnual proxy statement filed for 2026 shareholder meeting, detailing executive compensation, governance, and 2025 performance.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $1.27B | |
| Net income · FY2025 | $759M | |
| Number of hospitals · 2026-03-10 | 174 | |
| New beds added · FY2025 | 340 | |
| Expanded beds · FY2025 | 177 | |
| Nurse turnover reduction · FY2025 | $20.00 | |
| CEO pay ratio · FY2025 | $203.00 | |
| 5-year cumulative TSR · FY2025 | $170.02 |
Risks flagged
Regulatory and reimbursement risk
“Healthcare is a highly regulated industry. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments.” · word for word
Workforce composition risk
“Approximately 43% of our workforce consists of employees working less than full-time, which is a common employment arrangement in the healthcare services sector.” · word for word
26 Feb 202610-KNet operating revenues $3.69B; Net income $759M; Operating cash flow $1.18B; Guidance: Capex guidance for 2026: $920M to $995M, up from $736M in 2025open
Figures in the filing · each found in the filing text
| Net operating revenues · FY2025 | $3.69B | |
| Net income · FY2025 | $759M | |
| Operating cash flow · FY2025 | $1.18B | |
| Adjusted EBITDA · FY2025 | $1.27B | |
| Capital expenditures · FY2025 | $736M | |
| Number of hospitals · FY2025 | 173 | |
| Long-term debt · FY2025 | $2.07B | |
| Free cash flow · FY2025 | $441M |
Guidance
Capex guidance for 2026: $920M to $995M, up from $736M in 2025
Capex guidance raised significantly, indicating management confidence in demand and expansion.
Risks flagged
Payer mix shift to lower reimbursement
“We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our reimbursement, Net operating revenues, and profitability.” · word for word
Convener influence reducing patient volumes
“Conveners may influence referral source decisions on which post-acute setting to recommend, as well as how long to remain in a particular setting.” · word for word
Medicare/Medicaid reimbursement changes
“The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.” · word for word
5 Feb 20268-K · 2.02, 7.01Net operating revenue $1.54B (+10% y/y); Adjusted earnings per share $1.46 (+25% y/y); Adjusted EBITDA $336M (+16% y/y); Guidance: 2026 revenue guidance $6,365-$6,465M, adjusted EBITDA $1,340-$1,380Mearningsopen
Figures in the filing · each found in the filing text
| Net operating revenue · Q4-2025 | $1.54B | +10% y/y |
| Adjusted earnings per share · Q4-2025 | $1.46 | +25% y/y |
| Adjusted EBITDA · Q4-2025 | $336M | +16% y/y |
| Discharges · Q4-2025 | 67,238 | +5% y/y |
| Net patient revenue per discharge · Q4-2025 | $22273.00 | +4% y/y |
| Adjusted free cash flow · Q4-2025 | $235M | +24% y/y |
Guidance
2026 revenue guidance $6,365-$6,465M, adjusted EBITDA $1,340-$1,380M
2026 guidance implies continued strong growth with revenue up ~10% and adjusted EBITDA up ~10% at midpoint.
Risks flagged
Dependence on aging population trends and regulatory reimbursement environment.
“need for the services we provide continues to grow as the U.S. population ages” · word for word
1 Dec 20258-K · 7.01Encompass Health reiterates full-year 2025 guidance: net operating revenue $5,905M-$5,955M, adjusted EBITDA $1,235M-$1,255M, adjusted EPS $5.22-$5.37.open
Figures in the filing · each found in the filing text
| Net operating revenue · FY2025 | $5.91B | |
| Adjusted EBITDA · FY2025 | $1.24B | |
| Adjusted EPS · FY2025 | $5.22 |
Guidance
FY2025 net operating revenue $5,905M-$5,955M; adjusted EBITDA $1,235M-$1,255M; adjusted EPS $5.22-$5.37
Full-year 2025 guidance reaffirmed with no changes; stable outlook.
Risks flagged
Guidance unchanged; no new risks disclosed beyond standard forward-looking statements.
“Standard risk factors listed in forward-looking statements; no specific new risks.”
31 Oct 202510-QEncompass Health reported 9.4% revenue growth in Q3 2025, driven by volume and pricing, with continued expansion.earningsopen
Guidance
Management optimistic about long-term demand from aging demographics; no specific numeric guidance provided.
Risks flagged
Medicare reimbursement risk
“Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors... could decrease our revenues and adversely affect other operating results.” · word for word
Staffing shortage risk
“Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages... could increase staffing costs and adversely affect other financial and operating results” · word for word
29 Oct 20258-K · 2.02, 7.01Net operating revenue $1.48B (+9% y/y); Adjusted earnings per share $1.23 (+19% y/y); Adjusted EBITDA $300M (+11% y/y); Guidance: Revenue guidance raised to $5,905-$5,955M (from $5,880-$5,980); EBITDA to $1,235-$1,255M (from $1,220-$1,250);earningsopen
Figures in the filing · each found in the filing text
| Net operating revenue · Q3-2025 | $1.48B | +9% y/y |
| Adjusted earnings per share · Q3-2025 | $1.23 | +19% y/y |
| Adjusted EBITDA · Q3-2025 | $300M | +11% y/y |
| Discharges · Q3-2025 | 65,839 | +5% y/y |
| Same-store discharge growth · Q3-2025 | 2.9% | |
| Net patient revenue per discharge · Q3-2025 | $21679.00 | +3% y/y |
| Cash flows provided by operating activities · Q3-2025 | $271M | +1% y/y |
| Adjusted free cash flow · Q3-2025 | $174M | -8% y/y |
Guidance
Revenue guidance raised to $5,905-$5,955M (from $5,880-$5,980); EBITDA to $1,235-$1,255M (from $1,220-$1,250); EPS to $5.22-$5.37 (from $5.12-$5.34)
Full-year guidance raised across all metrics; strong volume growth and margin expansion
Risks flagged
Adjusted free cash flow declined 8.2% YoY despite revenue growth
“Adjusted free cash flow $174.2M vs $189.7M, -8.2%”
Encompass Health Corporation — questions
- What did Encompass Health Corporation file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance of existing $500M notes from May 2026.
Every figure on this page comes from Encompass Health Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.